Active Recombinant Human TNFSF14 protein, Fc-tagged

Cat.No. : TNFSF14-0342H
Product Overview : Recombinant Human TNFSF14 protein(Asp74-Val240), fused with Fc tag, was expressed in HEK293.
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : HEK293
Species : Human
Tag : Fc
Form : Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Bio-activity : Immobilized Human HVEM, His Tag at 5 μg/mL (100 μL/well) can bind Human LIGHT Protein, Fc Tag with a linear range of 0.2-4 ng/mL.
Molecular Mass : This protein carries a human IgG1 Fc tag at the N-terminus.The protein has a calculated MW of 82.6 kDa. The protein migrates as 116 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Proteinlength : Asp74-Val240
Endotoxin : Less than 1.0 EU per μg by the LAL method.
Purity : >90% as determined by SDS-PAGE.>90% as determined by SEC-MALS.
Storage : For long term, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after at:
-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
Protein length : Asp74-Val240
Gene Name : TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ]
Official Symbol : TNFSF14
Synonyms : TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML;
Gene ID : 8740
mRNA Refseq : NM_003807
Protein Refseq : NP_003798
MIM : 604520
UniProt ID : O43557

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
07/28/2020

    The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

    08/01/2018

      It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

      06/19/2016

        The ability to obtain enduring results positively influenced the depth of our investigations.

        Q&As (7)

        Ask a question
        What are the primary changes induced by TNFSF14 in the tumor microenvironment? 05/19/2022

        TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

        What challenges remain in utilizing TNFSF14 for cancer immunotherapy? 07/02/2021

        While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

        What does TNFSF14 stand for? 02/05/2021

        TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

        How can TNFSF14 synergize with other immunotherapy modalities? 02/22/2020

        TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

        In what context has TNFSF14 been utilized to combat cancer? 02/06/2018

        TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

        How long has TNFSF14 been in pre-clinical development? 06/11/2017

        TNFSF14 has been in pre-clinical development for over a decade.

        What is the primary promise of TNFSF14 in the field of cancer immunotherapy? 08/15/2016

        TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.

        Ask a Question for All TNFSF14 Products

        Required fields are marked with *

        My Review for All TNFSF14 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends